Search articles in News

Filter Articles

Open filters

Sections

Found 2,566 articles

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
- 27 Feb 2024
- Editor
Boehringer Ingelheim today announced that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase II trial [response difference: 64.8% (CI 51.1% - 78.6%), p<0.0001].2
GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC)
- 27 Feb 2024
- Editor
GSK plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea in adolescents and adults.
Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia
- 27 Feb 2024
- Editor
Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.
Innovative Trials unveils initiative to boost clinical trial patient retention in pediatric studies
- 21 Feb 2024
- Editor
A new initiative designed to boost clinical trial patient retention in pediatric studies has been announced today (19 February) by Innovative Trials, global specialists in clinical trial patient recruitment and retention acceleration.
What is Life Science?
- 21 Feb 2024
- Lucy Walters
Life science is a branch of science that focuses on the study of living organisms. It encompasses various disciplines such as genetics, zoology, botany, microbiology, ecology, biochemistry, and physiology.
BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart
- 21 Feb 2024
- Editor
BiVACOR®, a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
- 21 Feb 2024
- Editor
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel), followed by KEYTRUDA as a single agent for the treatment of patients with primary advanced or recurrent endometrial carcinoma.
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
- 21 Feb 2024
- Editor
AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO).
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
- 21 Feb 2024
- Editor
AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
- 20 Feb 2024
- Editor
Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor.
AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
- 20 Feb 2024
- Editor
AbbVie (NYSE: ABBV) announced that 17 AbbVie-sponsored abstracts, including new data from its inflammatory bowel disease (IBD) portfolio, have been accepted for presentation at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
- 20 Feb 2024
- Editor
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
- 20 Feb 2024
- Editor
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care. AstraZeneca’s has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
A Recruiter’s Guide to Hiring a Pharmaceutical Business Development Manager
- 15 Feb 2024
- Lucy Walters
In this guide, we explore the essential steps and considerations for you to keep in mind when searching for and selecting candidates for the role of pharmaceutical business development manager.
AI tool predicts function of unknown proteins
- 14 Feb 2024
- PharmiWeb Editor
KAUST develops DeepGO-SE, an AI to predict protein roles, aiding drug discovery and analysis of proteins with unknown functions.
Top 10 Pharmaceutical Companies in Australia 2024
- 14 Feb 2024
- Lucy Walters
Revenue in Australia’s pharmaceuticals market is projected to reach US$10.16bn in 2024, with the largest market being Oncology Drugs with a projected market volume of US$2.01bn. This revenue is expected to grow at an annual rate of 6.76% from 2024 to 2028, resulting in a market volume of US$13.20bn by 2028.
5 Pharmaceutical Sales Job Interview Questions and How to Answer Them
- 13 Feb 2024
- Lucy Walters
In this article, we explore 5 key interview questions often encountered in pharmaceutical sales, with examples to help you craft your own winning responses. Whether you’re a seasoned professional or a recent graduate, mastering these will help you stand out from the crowd and secure the position you’ve been working towards.
AbbVie Completes Acquisition of ImmunoGen
- 13 Feb 2024
- Editor
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN). With the completion of the acquisition, ImmunoGen is now part of AbbVie.
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
- 13 Feb 2024
- Editor
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
Justin Hely to be appointed as Chief Executive Officer of GenesisCare U.K. and Europe
- 12 Feb 2024
- Editor
GenesisCare, the UK’s leading private provider of cancer care, today announced the appointment of Justin Hely, MBA, as GenesisCare Chief Executive Officer of the UK and Europe.